Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04726332 · ClinicalTrials.gov registry record · Phase 1
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04726332 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 52 participants.
The verdict
NCT04726332, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to subjects with advanced solid tumors.
Interventions
- DRUG Fulvestrant
- DRUG Prednisone
- DRUG Abiraterone
- DRUG XL102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04726332
The ClinicalTrials.gov registry entry for NCT04726332 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fulvestrant is the first listed.
NCT04726332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04726332 about?
NCT04726332 is a clinical study titled "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)". This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to subjects with advanced solid tumors.
What is the current status of trial NCT04726332?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2021-02-10. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT04726332?
The interventions under investigation include: Fulvestrant (DRUG), Prednisone (DRUG), Abiraterone (DRUG), XL102 (DRUG).
Who is sponsoring clinical trial NCT04726332?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.